Upstream’s anti-malaria agents found effective in initial testing

Initial in vitro testing conducted by the Provincial Laboratory for Public Health (ProvLab) in Alberta, Canada, showed that Upstream’s potential drug candidates demonstrated anti-malarial activity in the nanomolar range. Activity in this range in a new class of drugs has the potential to represent an important advance in the treatment of resistant disease.

Stephanie Yanow, program leader at ProvLab, said: “These preliminary results indicating that Upstream’s novel structural class of anti-parasitic agents is demonstrating promising anti-malarial activity are encouraging, especially in view of the high unmet need for more effective anti-malarial therapies.”